Bristol-Myers Squibb: EMERGENT-4 & Key Elements Of Its Therapeutic Pipeline That Could Shape Its Future! 

Bristol-Myers Squibb’s (BMS) fourth quarter 2024 earnings call reveals a mixed outlook for the company. Positively, there were strong performances in certain areas of the company, reflecting a solid execution of its growth strategy. The growth portfolio delivered a double-digit increase, driven by key brands like Breyanzi, Camzyos, Reblozyl, and Opdualag. The launch of Cobenfy, a new treatment for schizophrenia, has also been promising, supported by robust Medicaid and Medicare access, which represent over 80% of lives covered in this category.